Karen Prange
CIK 1566083 · EVP&CEO Gl.AH.Med.Den.Sur.Grp · last filed 2026-06-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$10.16M
Companies
8
Total Filings
59
Lifetime Open-Market Net
-$1.24M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OM | Director | 29,334 | $4.69 | $137.6K | $0 | 2 | 2026-06-05 |
| ATRC | Director | 26,373 | $40.58 | $1.07M | -$352.6K | 11 | 2026-05-22 |
| EMBC | Director | 64,581 | $3.71 | $239.9K | $0 | 5 | 2026-02-13 |
| NEVRO CORP (NVRO) Delisted | Director | 0 | $5.84 | $0 | $0 | 6 | 2025-04-03 |
| ViewRay, Inc. (VRAY) Delisted | Director | 46,399 | $0.03 | $1.2K | $91.2K | 5 | 2023-07-21 |
| CANTEL MEDICAL CORP (CMD) Delisted | Director | 0 | $80.37 | $0 | $0 | 2 | 2021-06-02 |
| HSIC | EVP&CEO Gl.AH.Med.Den.Sur.Grp | 80,200 | $85.84 | $6.88M | $0 | 3 | 2018-03-06 |
| BSX | SVP&Pres, Uro & Pelvic Health | 39,395 | $46.52 | $1.83M | -$976.2K | 20 | 2016-03-08 |
Recent Filings · Page 4 of 6
59 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-05-26 | NEVRO CORP (NVRO) Delisted | Grant (A) | +1,167 | $0 | EDGAR |
| 2021-05-24 | ATRC | Grant (A) | +1,749 | $0 | EDGAR |
| 2020-07-31 | CANTEL MEDICAL CORP (CMD) Delisted | Grant (A) | +1,935 | $0 | EDGAR |
| 2020-05-22 | ATRC | Grant (A) | +2,452 | $0 | EDGAR |
| 2019-12-18 | NEVRO CORP (NVRO) Delisted | Grant (A) | +2,703 | $0 | EDGAR |
| 2019-12-05 | ATRC | Grant (A) | +5,902 | $0 | EDGAR |
| 2018-03-06 | HSIC | Grant (A) | +19,558 | $0 | EDGAR |
| 2017-03-08 | HSIC | Grant (A) | +8,777 | $0 | EDGAR |
| 2016-06-14 | HSIC | Grant (A) | +12,895 | $0 | EDGAR |
| 2016-03-08 | BSX | Sell (S) | −14,747 | -$254.7K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.